258 related articles for article (PubMed ID: 18941114)
1. Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody.
Goldenberg DM; Rossi EA; Stein R; Cardillo TM; Czuczman MS; Hernandez-Ilizaliturri FJ; Hansen HJ; Chang CH
Blood; 2009 Jan; 113(5):1062-70. PubMed ID: 18941114
[TBL] [Abstract][Full Text] [Related]
2. Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects.
Goldenberg DM; Morschhauser F; Wegener WA
Leuk Lymphoma; 2010 May; 51(5):747-55. PubMed ID: 20214444
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a novel humanized anti-CD20 antibody with potent anti-tumor activity against non-Hodgkin's lymphoma.
Zhang H; Song L; Ye H; Hu L; Liang W; Liu D
Cell Physiol Biochem; 2013; 32(3):645-54. PubMed ID: 24022075
[TBL] [Abstract][Full Text] [Related]
4. Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias.
Gupta P; Goldenberg DM; Rossi EA; Chang CH
Blood; 2010 Oct; 116(17):3258-67. PubMed ID: 20628151
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.
Stein R; Qu Z; Chen S; Rosario A; Shi V; Hayes M; Horak ID; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2004 Apr; 10(8):2868-78. PubMed ID: 15102696
[TBL] [Abstract][Full Text] [Related]
6. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.
Robak T; Robak E
BioDrugs; 2011 Feb; 25(1):13-25. PubMed ID: 21090841
[TBL] [Abstract][Full Text] [Related]
7. Novel humanized anti-CD20 antibody BM-ca binds to a unique epitope and exerts stronger cellular activity than others.
Kobayashi H; Matsunaga Y; Uchiyama Y; Nagura K; Komatsu Y
Cancer Med; 2013 Apr; 2(2):130-43. PubMed ID: 23634281
[TBL] [Abstract][Full Text] [Related]
8. Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma.
Sharkey RM; Karacay H; Johnson CR; Litwin S; Rossi EA; McBride WJ; Chang CH; Goldenberg DM
J Nucl Med; 2009 Mar; 50(3):444-53. PubMed ID: 19223402
[TBL] [Abstract][Full Text] [Related]
9. Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura.
Milani C; Castillo J
Curr Opin Mol Ther; 2009 Apr; 11(2):200-7. PubMed ID: 19330725
[TBL] [Abstract][Full Text] [Related]
10. Anti-CD22/CD20 Bispecific antibody with enhanced trogocytosis for treatment of Lupus.
Rossi EA; Chang CH; Goldenberg DM
PLoS One; 2014; 9(5):e98315. PubMed ID: 24841238
[TBL] [Abstract][Full Text] [Related]
11. Therapy of advanced B-lymphoma xenografts with a combination of 90Y-anti-CD22 IgG (epratuzumab) and unlabeled anti-CD20 IgG (veltuzumab).
Mattes MJ; Sharkey RM; Karacay H; Czuczman MS; Goldenberg DM
Clin Cancer Res; 2008 Oct; 14(19):6154-60. PubMed ID: 18829494
[TBL] [Abstract][Full Text] [Related]
12. Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma.
Barth MJ; Hernandez-Ilizaliturri FJ; Mavis C; Tsai PC; Gibbs JF; Deeb G; Czuczman MS
Br J Haematol; 2012 Feb; 156(4):490-8. PubMed ID: 22150234
[TBL] [Abstract][Full Text] [Related]
13. Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action.
Qu Z; Goldenberg DM; Cardillo TM; Shi V; Hansen HJ; Chang CH
Blood; 2008 Feb; 111(4):2211-9. PubMed ID: 18025153
[TBL] [Abstract][Full Text] [Related]
14. Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics.
Rossi EA; Goldenberg DM; Cardillo TM; Stein R; Wang Y; Chang CH
Cancer Res; 2008 Oct; 68(20):8384-92. PubMed ID: 18922911
[TBL] [Abstract][Full Text] [Related]
15. γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody.
Braza MS; Klein B; Fiol G; Rossi JF
Haematologica; 2011 Mar; 96(3):400-7. PubMed ID: 21109686
[TBL] [Abstract][Full Text] [Related]
16. Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma.
Negrea GO; Elstrom R; Allen SL; Rai KR; Abbasi RM; Farber CM; Teoh N; Horne H; Wegener WA; Goldenberg DM
Haematologica; 2011 Apr; 96(4):567-73. PubMed ID: 21173095
[TBL] [Abstract][Full Text] [Related]
17. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.
Mössner E; Brünker P; Moser S; Püntener U; Schmidt C; Herter S; Grau R; Gerdes C; Nopora A; van Puijenbroek E; Ferrara C; Sondermann P; Jäger C; Strein P; Fertig G; Friess T; Schüll C; Bauer S; Dal Porto J; Del Nagro C; Dabbagh K; Dyer MJ; Poppema S; Klein C; Umaña P
Blood; 2010 Jun; 115(22):4393-402. PubMed ID: 20194898
[TBL] [Abstract][Full Text] [Related]
18. Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101.
Dalle S; Reslan L; Besseyre de Horts T; Herveau S; Herting F; Plesa A; Friess T; Umana P; Klein C; Dumontet C
Mol Cancer Ther; 2011 Jan; 10(1):178-85. PubMed ID: 21220500
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma.
Li B; Zhao L; Guo H; Wang C; Zhang X; Wu L; Chen L; Tong Q; Qian W; Wang H; Guo Y
Blood; 2009 Dec; 114(24):5007-15. PubMed ID: 19828699
[TBL] [Abstract][Full Text] [Related]
20. Novel humanized anti-CD20 monoclonal antibodies with unique germline VH and VL gene recruitment and potent effector functions.
Nishida M; Teshigawara K; Niwa O; Usuda S; Nakamura T; Ralph P; Newman R; Padlan EA
Int J Oncol; 2008 Jun; 32(6):1263-74. PubMed ID: 18497988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]